| Gastrointestinal Stromal Tumors
Ayvakit vs Qinlock
Side-by-side clinical, coverage, and cost comparison for gastrointestinal stromal tumors.Deep comparison between: Ayvakit vs Qinlock with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQinlock has a higher rate of injection site reactions vs Ayvakit based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qinlock but not Ayvakit, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ayvakit
Qinlock
At A Glance
Oral
Daily
KIT/PDGFRA kinase inhibitor
Oral
Daily
KIT/PDGFRA kinase inhibitor
Indications
- Gastrointestinal Stromal Tumors
- Aggressive Systemic Mastocytosis
- Indolent Systemic Mastocytosis
- Gastrointestinal Stromal Tumors
Dosing
Gastrointestinal Stromal Tumors 300 mg orally once daily in patients with PDGFRA exon 18 mutation-positive unresectable or metastatic GIST; continue until disease progression or unacceptable toxicity.
Aggressive Systemic Mastocytosis 200 mg orally once daily; continue until disease progression or unacceptable toxicity.
Indolent Systemic Mastocytosis 25 mg orally once daily.
Gastrointestinal Stromal Tumors 150 mg orally once daily with or without food until disease progression or unacceptable toxicity; tablets should be swallowed whole.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) in GIST edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, increased lacrimation, abdominal pain, constipation, rash, dizziness, hair color changes
Most common (>=20%) in AdvSM edema, diarrhea, nausea, fatigue/asthenia
Most common (>=10%) in ISM eye edema, dizziness, peripheral edema, flushing
Serious intracranial hemorrhage, anemia, pleural effusion, sepsis, gastrointestinal hemorrhage, subdural hematoma, ascites, pneumonia, acute kidney injury, encephalopathy
Most common (>=20%) Alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, vomiting
Serious Abdominal pain, anemia, nausea, vomiting
Pharmacology
Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA, and PDGFRA D842 mutants (IC50s <25 nM), inhibiting autophosphorylation and constitutive activation of these receptors to suppress tumor and mast cell proliferation; other potential targets include wild-type KIT, PDGFRB, and CSFR1.
Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations, and also inhibits PDGFRB, TIE2, VEGFR2, and BRAF in vitro.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ayvakit
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Qinlock
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ayvakit
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Qinlock
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Ayvakit
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Qinlock
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gastrointestinal Stromal Tumors (GIST) - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Gastrointestinal Stromal Tumors (GIST) - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AyvakitView full Ayvakit profile
QinlockView full Qinlock profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.